Oramed Pharmaceuticals Inc
NASDAQ:ORMP

Watchlist Manager
Oramed Pharmaceuticals Inc Logo
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
Watchlist
Price: 3.07 USD 1.15% Market Closed
Market Cap: 122.2m USD

Profitability Summary

Oramed Pharmaceuticals Inc's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Oramed Pharmaceuticals Inc

Revenue
2m USD
Cost of Revenue
-2m USD
Gross Profit
13k USD
Operating Expenses
-13m USD
Operating Income
-13m USD
Other Expenses
56.9m USD
Net Income
43.9m USD

Margins Comparison
Oramed Pharmaceuticals Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
125.4m USD
1%
-651%
2 193%
US
Eli Lilly and Co
NYSE:LLY
971.9B USD
83%
44%
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
509.1B USD
68%
27%
27%
CH
Roche Holding AG
SIX:ROG
252.3B CHF
74%
34%
15%
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP
82%
24%
16%
CH
Novartis AG
SIX:NOVN
202.4B CHF
76%
33%
26%
US
Merck & Co Inc
NYSE:MRK
249.5B USD
79%
38%
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
82%
42%
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
147B USD
75%
29%
16%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Oramed Pharmaceuticals Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Oramed Pharmaceuticals Inc
NASDAQ:ORMP
125.4m USD
24%
23%
-7%
-20%
US
Eli Lilly and Co
NYSE:LLY
971.9B USD
97%
19%
42%
25%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
509.1B USD
33%
13%
18%
13%
CH
Roche Holding AG
SIX:ROG
252.3B CHF
33%
10%
31%
19%
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP
22%
9%
18%
15%
CH
Novartis AG
SIX:NOVN
202.4B CHF
33%
14%
25%
18%
US
Merck & Co Inc
NYSE:MRK
249.5B USD
40%
15%
26%
21%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
71%
23%
57%
28%
IE
Endo International PLC
LSE:0Y5F
209B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
147B USD
11%
5%
11%
10%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less